Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2009

01.05.2009 | Preclinical Study

Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives

verfasst von: A-Yong Cao, Juan Huang, Zhen Hu, Wen-Feng Li, Zhong-Liang Ma, Li-Li Tang, Bin Zhang, Feng-Xi Su, Jie Zhou, Gen-Hong Di, Kun-Wei Shen, Jiong Wu, Jin-Song Lu, Jian-Min Luo, Wen-Tao Yuan, Zhen-Zhou Shen, Wei Huang, Zhi-Ming Shao

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

The proper interaction between BRIP1/BACH1 and BRCA1 protein has been found to be crucial for BRCA1-mediated DNA double-strand break repair and BRIP1/BACH1 mutations were estimated to confer a relative risk for breast cancer of 2.0 in western populations. In Chinese population, BRCA1 mutations could explain a relatively large proportion of inherited breast cancer cases in comparison with BRCA2 mutations, which probably deduced a hypothesis that those genes involved in BRCA1-mediated DNA repair pathway might play a more significant role in the etiology of Chinese breast cancer. To investigate the contribution of BRIP1/BACH1 mutations to the predisposition of Chinese non-BRCA1/BRCA2 hereditary breast cancer, we screened all the coding exons and adjacent intronic splice junction regions of BRIP1/BACH1 in 357 Chinese women with early-onset breast cancer or affected relatives from five different breast disease clinical centers in China, using PCR-DHPLC and DNA sequencing analysis. Some genetic variants identified in the cases were then studied in 864 normal controls with no personal or family history of breast cancer. We found no protein-truncated mutations in our population, while a novel recurrent non-synonymous variant, Q944E, was detected in two independent families in contrast with none in the controls, interestingly, this alteration occurs in the BRCA1 binding domain of the BACH1 protein. Then a further study performed on the two mutation positive families revealed the partial co-segregation of this mutation allele with cancer. The novel alteration Q944E identified in our study possibly represents a rare disease-related allele, nevertheless functional analysis is still warranted to resolve the ability of this altered BACH1 protein to bind BRCA1. Altogether, the results of our study indicated that germline mutations in BRIP1/BACH were extremely rare in Chinese population and there was no evidence for the recommendation of BRIP1/BACH1 for genetic testing in Chinese.
Literatur
1.
2.
Zurück zum Zitat Li WF, Hu Z, Rao NY et al (2007) The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. Breast Cancer Res Treat. doi:10.1007/s10549-007-9708-3 (in press) Li WF, Hu Z, Rao NY et al (2007) The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. Breast Cancer Res Treat. doi:10.​1007/​s10549-007-9708-3 (in press)
3.
Zurück zum Zitat Cantor SB, Bell DW, Ganesan S et al (2001) A novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell 105:149–160PubMedCrossRef Cantor SB, Bell DW, Ganesan S et al (2001) A novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell 105:149–160PubMedCrossRef
4.
Zurück zum Zitat Litman R, Peng M, Jin Z et al (2001) BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. Cancer Cell 8:255–265CrossRef Litman R, Peng M, Jin Z et al (2001) BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. Cancer Cell 8:255–265CrossRef
5.
Zurück zum Zitat Bridge WL, Vandenberg CJ, Franklin RJ et al (2001) The BRIP1 helicase functions independently of BRCA1 in the Fanconi anemia pathway for DNA crosslink repair. Nat Genet 37:953–957CrossRef Bridge WL, Vandenberg CJ, Franklin RJ et al (2001) The BRIP1 helicase functions independently of BRCA1 in the Fanconi anemia pathway for DNA crosslink repair. Nat Genet 37:953–957CrossRef
6.
Zurück zum Zitat Seal S, Thompson D, Renwick A et al (2001) Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 38:1239–1241CrossRef Seal S, Thompson D, Renwick A et al (2001) Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 38:1239–1241CrossRef
7.
Zurück zum Zitat Levitus M, Waisfisz Q, Godthelp BC et al (2005) The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. Nat Genet 37:934–935PubMedCrossRef Levitus M, Waisfisz Q, Godthelp BC et al (2005) The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. Nat Genet 37:934–935PubMedCrossRef
8.
Zurück zum Zitat Serova OM, Mazoyer S, Puget N et al (1997) Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes? Am J Hum Genet 60:486–495PubMed Serova OM, Mazoyer S, Puget N et al (1997) Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes? Am J Hum Genet 60:486–495PubMed
9.
Zurück zum Zitat Vehmanen P, Friedman LS, Eerola H et al (1997) Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. Hum Mol Genet 6:2309–2315PubMedCrossRef Vehmanen P, Friedman LS, Eerola H et al (1997) Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. Hum Mol Genet 6:2309–2315PubMedCrossRef
10.
Zurück zum Zitat Rahman N, Stratton MR (1998) The genetics of breast cancer susceptibility. Annu Rev Genet 32:95–121PubMedCrossRef Rahman N, Stratton MR (1998) The genetics of breast cancer susceptibility. Annu Rev Genet 32:95–121PubMedCrossRef
11.
Zurück zum Zitat Lewis AG, Flanagan J, Marsh A et al (2005) Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer. Breast Cancer Res 7:R1005–R1016PubMedCrossRef Lewis AG, Flanagan J, Marsh A et al (2005) Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer. Breast Cancer Res 7:R1005–R1016PubMedCrossRef
12.
Zurück zum Zitat Karppinen SM, Vuosku J, Heikkinen K et al (2003) No evidence of involvement of germline BACH1 mutations in Finnish breast and ovarian cancer families. Eur J Cancer 39:366–371PubMedCrossRef Karppinen SM, Vuosku J, Heikkinen K et al (2003) No evidence of involvement of germline BACH1 mutations in Finnish breast and ovarian cancer families. Eur J Cancer 39:366–371PubMedCrossRef
13.
Zurück zum Zitat Rutter JL, Smith AM, Dávila MR et al (2003) Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals. Hum Mutat 22:121–128PubMedCrossRef Rutter JL, Smith AM, Dávila MR et al (2003) Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals. Hum Mutat 22:121–128PubMedCrossRef
14.
Zurück zum Zitat Luo L, Lei H, Du Q et al (2002) No mutations in the BACH1 gene in BRCA1 and BRCA2 negative breast-cancer families linked to 17q22. Int J Cancer 98:638–639PubMedCrossRef Luo L, Lei H, Du Q et al (2002) No mutations in the BACH1 gene in BRCA1 and BRCA2 negative breast-cancer families linked to 17q22. Int J Cancer 98:638–639PubMedCrossRef
15.
Zurück zum Zitat Vahteristo P, Yliannala K, Tamminen A et al (2006) BACH1 Ser919Pro variant and breast cancer risk. BMC Cancer 6:19PubMedCrossRef Vahteristo P, Yliannala K, Tamminen A et al (2006) BACH1 Ser919Pro variant and breast cancer risk. BMC Cancer 6:19PubMedCrossRef
16.
Zurück zum Zitat Yu X, Chini CC, He M et al (2003) The BRCT domain is a phospho-protein binding domain. Science 302:639–642PubMedCrossRef Yu X, Chini CC, He M et al (2003) The BRCT domain is a phospho-protein binding domain. Science 302:639–642PubMedCrossRef
17.
Zurück zum Zitat Klein B, Weirich G, Brauch H (2001) DHPLC-based germline mutation screening in the analysis of the VHL tumor suppressor gene: usefulness and limitations. Hum Genet 108:376–384PubMedCrossRef Klein B, Weirich G, Brauch H (2001) DHPLC-based germline mutation screening in the analysis of the VHL tumor suppressor gene: usefulness and limitations. Hum Genet 108:376–384PubMedCrossRef
18.
Zurück zum Zitat Xiao W, Oefner PJ (2001) Denaturing high-performance liquid chromatography: a review. Hum Mutat 17:439–474PubMedCrossRef Xiao W, Oefner PJ (2001) Denaturing high-performance liquid chromatography: a review. Hum Mutat 17:439–474PubMedCrossRef
19.
Zurück zum Zitat Song CG, Hu Z, Wu J et al (2006) The prevalence of BRCA1 and BRCA2 mutations in eastern Chinese women with breast cancer. J Cancer Res Clin Oncol 32:617–626CrossRef Song CG, Hu Z, Wu J et al (2006) The prevalence of BRCA1 and BRCA2 mutations in eastern Chinese women with breast cancer. J Cancer Res Clin Oncol 32:617–626CrossRef
20.
Zurück zum Zitat Hu Z, Wu J, Liu CH et al (2003) The analysis of BRCA1 mutations in eastern Chinese patients with early onset breast cancer and affected relatives. Hum Mutat 22:104PubMedCrossRef Hu Z, Wu J, Liu CH et al (2003) The analysis of BRCA1 mutations in eastern Chinese patients with early onset breast cancer and affected relatives. Hum Mutat 22:104PubMedCrossRef
Metadaten
Titel
Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives
verfasst von
A-Yong Cao
Juan Huang
Zhen Hu
Wen-Feng Li
Zhong-Liang Ma
Li-Li Tang
Bin Zhang
Feng-Xi Su
Jie Zhou
Gen-Hong Di
Kun-Wei Shen
Jiong Wu
Jin-Song Lu
Jian-Min Luo
Wen-Tao Yuan
Zhen-Zhou Shen
Wei Huang
Zhi-Ming Shao
Publikationsdatum
01.05.2009
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2009
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-008-0052-z

Weitere Artikel der Ausgabe 1/2009

Breast Cancer Research and Treatment 1/2009 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.